These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 36115452)

  • 1. Architecting novel multilayer nanosponges for co-administration of two drugs managing high-risk type II diabetes mellitus patients suffering from cardiovascular diseases.
    Hammad RW; Sanad RA; Abdelmalak NS; Latif R
    Int J Biol Macromol; 2022 Nov; 220():1429-1443. PubMed ID: 36115452
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cubosomal functionalized block copolymer platform for dual delivery of linagliptin and empagliflozin: Recent advances in synergistic strategies for maximizing control of high-risk type II diabetes.
    Hammad RW; Sanad RA; Abdelmalak NS; Latif R
    Drug Deliv Transl Res; 2024 Mar; 14(3):678-695. PubMed ID: 37805954
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single-pill combination therapy for type 2 diabetes mellitus: linagliptin plus empagliflozin.
    Aronson R
    Curr Med Res Opin; 2015 May; 31(5):901-11. PubMed ID: 25775379
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Empagliflozin/Linagliptin: A Review in Type 2 Diabetes.
    Kim ES; Deeks ED
    Drugs; 2015 Sep; 75(13):1547-57. PubMed ID: 26323340
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Triple fixed-dose combination empagliflozin, linagliptin, and metformin for patients with type 2 diabetes.
    Lingvay I; Beetz N; Sennewald R; Schuler-Metz A; Bertulis J; Loley C; Lang B; Lippert C; Lee J; Manning LS; Terada D
    Postgrad Med; 2020 May; 132(4):337-345. PubMed ID: 32366156
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic drug evaluation of empagliflozin plus linagliptin for the treatment of type 2 diabetes.
    Rizos CV; Filippatos TD; Elisaf MS
    Expert Opin Drug Metab Toxicol; 2018 Jan; 14(1):117-125. PubMed ID: 29241374
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Empagliflozin and linagliptin combination therapy for treatment of patients with type 2 diabetes mellitus.
    Triplitt C; Solis-Herrera C; Cersosimo E; Abdul-Ghani M; Defronzo RA
    Expert Opin Pharmacother; 2015; 16(18):2819-33. PubMed ID: 26583910
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Flourimetric study on antidiabetic combined drugs; empagliflozin and linagliptin in their pharmaceutical formulation and human plasma.
    Elmasry MS; Hasan MA; Hassan WS; Merey HA; Nour IM
    Spectrochim Acta A Mol Biomol Spectrosc; 2021 Mar; 248():119258. PubMed ID: 33310272
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and tolerability of empagliflozin and linagliptin combination therapy in patients with type 2 diabetes mellitus: a pooled analysis of data from five randomized, controlled clinical trials.
    Watada H; Yamauchi T; Yamamoto F; Taniguchi A; Yarush L; Heilmann C; Yasui A
    Expert Opin Drug Saf; 2020 Sep; 19(9):1193-1202. PubMed ID: 32552153
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Empagliflozin/Linagliptin: Combination therapy in patients with type 2 diabetes.
    Tan X; Hu J
    Ann Endocrinol (Paris); 2016 Oct; 77(5):557-562. PubMed ID: 27062036
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of efficacy and safety of empagliflozin vs linagliptin added to premixed insulin in patients with uncontrolled type 2 diabetes: A randomized, open-label study.
    Liu SC; Lee CC; Chuang SM; Sun FJ; Zeng YH
    Diabetes Metab; 2021 May; 47(3):101184. PubMed ID: 32827752
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A safety evaluation of empagliflozin plus linagliptin for treating type 2 diabetes.
    Gallwitz B
    Expert Opin Drug Saf; 2017 Dec; 16(12):1399-1405. PubMed ID: 28934557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Empagliflozin/linagliptin single-pill combination therapy for patients with type 2 diabetes mellitus.
    Jain RK
    Expert Opin Pharmacother; 2017 Apr; 18(6):545-549. PubMed ID: 28375658
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized, open-label, crossover study to evaluate the pharmacokinetics of empagliflozin and linagliptin after coadministration in healthy male volunteers.
    Friedrich C; Metzmann K; Rose P; Mattheus M; Pinnetti S; Woerle HJ
    Clin Ther; 2013 Jan; 35(1):A33-42. PubMed ID: 23328275
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and Tolerability of Combinations of Empagliflozin and Linagliptin in Patients with Type 2 Diabetes: Pooled Data from Two Randomized Controlled Trials.
    DeFronzo RA; Lee C; Kohler S
    Adv Ther; 2018 Jul; 35(7):1009-1022. PubMed ID: 29949041
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Renal hemodynamic effects differ between antidiabetic combination strategies: randomized controlled clinical trial comparing empagliflozin/linagliptin with metformin/insulin glargine.
    Ott C; Jung S; Korn M; Kannenkeril D; Bosch A; Kolwelter J; Striepe K; Bramlage P; Schiffer M; Schmieder RE
    Cardiovasc Diabetol; 2021 Sep; 20(1):178. PubMed ID: 34481498
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Single-pill Combination of Empagliflozin and Linagliptin in Real World Indian Type 2 Diabetes Patient (GRID).
    Kovil R; Saboo B; Shah K; Padhye D; Chudasama D; Raj V; Shaikh N
    J Assoc Physicians India; 2020 Oct; 68(10):53-55. PubMed ID: 32978926
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination of empagliflozin and linagliptin improves blood pressure and vascular function in type 2 diabetes.
    Jung S; Bosch A; Kannenkeril D; Karg MV; Striepe K; Bramlage P; Ott C; Schmieder RE
    Eur Heart J Cardiovasc Pharmacother; 2020 Nov; 6(6):364-371. PubMed ID: 31816038
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SGLT2 inhibitor/DPP-4 inhibitor combination therapy - complementary mechanisms of action for management of type 2 diabetes mellitus.
    Dey J
    Postgrad Med; 2017 May; 129(4):409-420. PubMed ID: 28322073
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SGLT2 Inhibitor Empagliflozin and DPP4 Inhibitor Linagliptin Reactivate Glomerular Autophagy in
    Korbut AI; Taskaeva IS; Bgatova NP; Muraleva NA; Orlov NB; Dashkin MV; Khotskina AS; Zavyalov EL; Konenkov VI; Klein T; Klimontov VV
    Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32340263
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.